Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853216 | 0.75 | KDM4E (0.41) | LMNA | |
| SCHEMBL11985856 | 0.75 | GAA (0.33) | — | |
| SCHEMBL29441275 | 0.75 | GAA (0.33) | — | |
| SCHEMBL25943636 | 0.74 | KDM4E (0.32) | — | |
| SCHEMBL25928074 | 0.74 | ALDH1A1 (0.32) | — | |
| SCHEMBL25928168 | 0.74 | ALDH1A1 (0.30) | LMNA | |
| SCHEMBL25938570 | 0.74 | GABRA1 (0.33) | LMNA | |
| SCHEMBL9277193 | 0.71 | NQO2 (0.38) | LMNA | |
| SCHEMBL1143077 | 0.71 | NOS2 (0.44) | LMNA | |
| SCHEMBL30930705 | 0.71 | NOS2 (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2769980-A1 | PYRAZOLOQUINOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-08-27 | — | — | EP | disclosed |
| EP-2769980-A1 | PYRAZOLOQUINOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-08-27 | — | — | EP | disclosed |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-8563565-B2 | Pyrazoloquinoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563565-B2 | Pyrazoloquinoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563565-B2 | Pyrazoloquinoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-06-06 | — | — | US | disclosed |
| WO-2013051639-A1 | PYRAZOLOQUINOLINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2013-04-11 | — | — | WO | disclosed |
| US-7498346-B2 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | GENZYME CORPORATION (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1896023-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138259-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| US-20050277668-A1 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277668-A1 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | CCR5, CCR2, CXCR3 | LMNA 3892/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | LMNA 1759/4885 |
| US-20130143907-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | LMNA 4210/4885 |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | LMNA 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.